Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity With Calcified Coronary Plaque in Young Adults: The CARDIA Study

Objective— To examine the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity with calcified coronary plaque in young adults. Methods and Results— Nested case-control study among CARDIA participants at the year 15 examination (2000 to 2001, 33 to 45 years old). Cases (n=266) were those with and controls (n=266) those without evidence of calcified coronary plaque by computed tomography matched 1:1 on sex and race. Lp-PLA2 mass and activity were significantly higher in cases (296±101 ng/mL and 36.4±12.3 nmol/mL per minute) than in controls (267±80 ng/mL and 32.9±11.8 nmol/mL per minute). In age-adjusted conditional logistic regression, the odds ratio (OR) of calcified coronary plaque per 1 standard deviation (SD) increment was 1.40 (95% CI, 1.17 to 1.67) and 1.39 (95% CI, 1.14 to 1.70) for Lp-PLA2 mass and activity, respectively. After adjusting for multiple covariates including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, and C-reactive protein, a statistically significant association remained for Lp-PLA2 mass (OR, 1.28; 95% CI, 1.03 to 1.60) but not for activity (OR, 1.09; 95% CI, 0.84 to 1.42). No evidence was found for interaction between Lp-PLA2 mass or activity with LDL-C as predictors of calcified coronary plaque. Conclusion— An independent association of Lp-PLA2 mass with calcified coronary plaque existed in young adults. Therefore, Lp-PLA2 mass may be a useful marker of subclinical cardiovascular risk.

[1]  A. Localio,et al.  Coronary artery calcification and cardiovascular risk factors: impact of the analytic approach. , 2004, Atherosclerosis.

[2]  Heejung Bang,et al.  Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study , 2004, Circulation.

[3]  I. Challis,et al.  Mildly oxidised LDL induces more macrophage death than moderately oxidised LDL: roles of peroxidation, lipoprotein‐associated phospholipase A2 and PPARγ , 2003, FEBS letters.

[4]  A. Localio,et al.  C-Reactive Protein and Coronary Artery Calcification: The Study of Inherited Risk of Coronary Atherosclerosis (SIRCA) , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[5]  S. Blair,et al.  Comparison of coronary artery calcium detected by electron beam tomography in patients with to those without symptomatic coronary heart disease. , 2003, The American journal of cardiology.

[6]  F. Cambien,et al.  Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. , 2003, Journal of lipid research.

[7]  Kiang Liu,et al.  Electron-Beam Tomography Coronary Artery Calcium and Cardiac Events: A 37-Month Follow-Up of 5635 Initially Asymptomatic Low- to Intermediate-Risk Adults , 2003, Circulation.

[8]  M. Elisaf,et al.  Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins Published, JLR Papers in Press, March 1, 2003. DOI 10.1194/jlr.M200452-JLR200 , 2003, Journal of Lipid Research.

[9]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[10]  J. Goudevenos,et al.  Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[11]  R. Wolfert,et al.  Lp-PLA2: an emerging biomarker of coronary heart disease , 2002, Expert review of molecular diagnostics.

[12]  J. Manson,et al.  A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. , 2001, Journal of the American College of Cardiology.

[13]  P. O'Malley,et al.  C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis. , 2001, American heart journal.

[14]  L. Tjoelker,et al.  Platelet-activating factor acetylhydrolases in health and disease. , 2000, Biochimica et biophysica acta.

[15]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[16]  P. Ridker,et al.  Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. , 2000, Journal of the American College of Cardiology.

[17]  P. Peplow.  Regulation of platelet-activating factor (PAF) activity in human diseases by phospholipase A2 inhibitors, PAF acetylhydrolases, PAF receptor antagonists and free radical scavengers. , 1999, Prostaglandins, leukotrienes, and essential fatty acids.

[18]  J. Qiao,et al.  Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[19]  J. Qiao,et al.  Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[20]  D. Tew,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. , 1999, The Biochemical journal.

[21]  M. Budoff,et al.  Coronary calcium and standard risk factors in symptomatic patients referred for coronary angiography. , 1998, American heart journal.

[22]  M. Yokota,et al.  Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. , 1998, Metabolism: clinical and experimental.

[23]  V. Mooser,et al.  Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. , 1997, Journal of lipid research.

[24]  U. Hedin,et al.  Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[25]  R. Detrano,et al.  Electron beam computed tomographic coronary calcium as a predictor of coronary events: comparison of two protocols. , 1997, Circulation.

[26]  G. Zimmerman,et al.  Platelet-activating Factor Acetylhydrolases* , 1997, The Journal of Biological Chemistry.

[27]  M. Triggiani,et al.  Characterization of platelet-activating factor acetylhydrolase in human bronchoalveolar lavage. , 1997, American journal of respiratory and critical care medicine.

[28]  G. Olaison,et al.  Platelet-activating factor acetylhydrolase activity in intestinal mucosa and plasma of patients with Crohn's disease. , 1996, Digestion.

[29]  V. Fuster,et al.  Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. , 1996, Circulation.

[30]  E. Ninio,et al.  PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[31]  G. Zimmerman,et al.  Anti-inflammatory properties of a platelet-activating factor acetylhydrolase , 1995, Nature.

[32]  A. Dyer,et al.  Cardiovascular risk factors in young adults. The CARDIA baseline monograph. , 1991, Controlled clinical trials.

[33]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[34]  D. Jacobs,et al.  Recruitment in the Coronary Artery Disease Risk Development in Young Adults (Cardia) Study. , 1987, Controlled clinical trials.

[35]  J. Albers,et al.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. , 1982, Clinical chemistry.

[36]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[37]  C. Cori,et al.  A comparative study of hexokinase from yeast and animal tissues. , 1950, The Journal of biological chemistry.

[38]  R. Detrano,et al.  Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. , 2005, Radiology.

[39]  M. H.,et al.  LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 AS AN INDEPENDENT PREDICTOR OF CORONARY HEART DISEASE , 2000 .

[40]  R. Tracy,et al.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.

[41]  A. Dyer,et al.  Alcohol intake and blood pressure in young adults: the CARDIA Study. , 1990, Journal of clinical epidemiology.

[42]  G. Camussi,et al.  Release of platelet-activating factor in systemic lupus erythematosus. , 1990, International archives of allergy and applied immunology.

[43]  D. Stafforini,et al.  Platelet-activating factor acetylhydrolase from human plasma. , 1990, Methods in enzymology.

[44]  S B Hulley,et al.  CARDIA: study design, recruitment, and some characteristics of the examined subjects. , 1988, Journal of clinical epidemiology.

[45]  G. Warnick.  Enzymatic methods for quantification of lipoprotein lipids. , 1986, Methods in enzymology.

[46]  Warnick Gr.  Enzymatic methods for quantification of lipoprotein lipids. , 1986 .